Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ABOS Acumen Pharmaceuticals
5.450-0.070-1.27%
Close
01/27 16:00 ET
5.4500.0000.00%
Post Mkt Price 01/27 16:41 ET
High
5.810
Open
5.450
Turnover
325.22K
Low
5.300
Pre Close
5.520
Volume
58.63K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Acumen Pharmaceuticals (NASDAQ:ABOS) Versus Immunovant (NASDAQ:IMVT) Critical Review
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Immunovant (NASDAQ:IMVT – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the s
Acumen Pharmaceuticals (NASDAQ:ABOS) & Achilles Therapeutics (NASDAQ:ACHL) Head-To-Head Analysis
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Achilles Therapeutics (NASDAQ:ACHL – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two co
Acumen Pharmaceuticals Appoints Derrell Porter to Its Board of Directors
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Growth in Short Interest
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 875,700 sh
5 Value Stocks In The Healthcare Sector
What are Value Stocks?A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors ar
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 9.1% in November
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 704,7
Woodline Partners LP Sells 75,066 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
Woodline Partners LP decreased its stake in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) by 15.0% during the 2nd quarter, according to its most recent 13F filing with the Securi
Virtu Financial LLC Buys New Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
Virtu Financial LLC bought a new stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commiss
Credit Suisse Trims Acumen Pharmaceuticals' Price Target to $16 From $17, Keeps Outperform Rating
09:56 AM EST, 11/15/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Acumen Pharmaceuticals Is Maintained at Outperform by Credit Suisse
Company Overview
More
Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.
CEO： Mr. Daniel O'Connell
Market： NASDAQ
Listing Date： 07/01/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet